Biocon Limited — Important, 30-12-2024: Updates

Biocon Biologics has fulfilled all deferred milestones related to its acquisition agreement with Viatris, marking the complete and final remittance of considerations associated with the deal. This accomplishment strengthens Biocon's strategic position and underscores its commitment to expansion through key acquisitions. The successful completion of this milestone is expected to enhance Biocon Biologics' operational capabilities and facilitate growth opportunities moving forward. Investors should view this development positively as it reflects the company’s adherence to planned strategic initiatives.